caa a22 4500 445796715 CHVBK 20180317145127.0 cr unu---uuuuu 170323e20110501xx s 000 0 eng 10.1007/s10620-010-1446-4 doi (NATIONALLICENCE)springer-10.1007/s10620-010-1446-4 Comparative Evaluation of Different Doses of Green Tea Extract Alone and in Combination with Sulfasalazine in Experimentally Induced Inflammatory Bowel Disease in Rats [Elektronische Daten] [D. Byrav, B. Medhi, K. Vaiphei, A. Chakrabarti, K. Khanduja] Background: The exact etiopathology of inflammatory bowel disease is still unclear. Most of the therapies present are directed towards symptomatic improvement. Surgical therapy in the form of restorative proctocolectomy is reserved for the terminal stage disease, which is unresponsive to medical therapy. The present study was conducted to evaluate the effect of green tea in experimentally induced inflammatory bowel disease. Methods: A total of 36 animals were included in the study. The animals were divided into five groups (n=6): Group I-Vehicle (ethanol), group II-TNBS+ethanol, group III-green tea-treated group was divided into two sub-groups on the basis of different doses: group IIIA-TNBS+green tea (35mg/kg), group IIIB-TNBS+green tea (70mg/kg), group IV-TNBS+sulfasalazine (360mg/kg), group V-TNBS+sulfasalazine (360mg/kg)+green tea (least effective dose found in group III). After completion of 2 weeks of treatment, the rats were killed under ether anesthesia by cervical dislocation for assessment of intestinal inflammation, histological analysis, myeloperoxidase assay, malondialdehyde assay, and TNF-α estimation. Results: The study showed that green tea alone and in combination with sulfasalazine reduced inflammatory changes induced by tri nitro benzene sulfonic acid in rats. This reduction is associated with reduced malondialdehyde, lipid peroxidation, and TNF-α. This correlates well with both gross morphological and histopathological scores. Conclusions: The authors concluded that a combination of green tea extract with sulfasalazine showed greater efficacy than single drug treatment. Springer Science+Business Media, LLC, 2010 Crohn's disease nationallicence Ulcerative colitis nationallicence Tumor necrosis factor nationallicence Myeloperoxidase nationallicence Malondialdehyde nationallicence Interleukin-1 nationallicence ANOVA : Analysis of variance nationallicence AP-1 : Activator protein nationallicence CD : Crohn's disease nationallicence CAM : Complementary and alternative medicine nationallicence CPCSEA : Committee for the Purpose of Control and Supervision on Experiments on Animals nationallicence DNA : Deoxyribonucleic acid nationallicence EGCG : Epigallocatechin gallate nationallicence EGC : Epigallocatechin nationallicence ECG : Epicatechin gallate nationallicence ELISA : Enzyme-linked immunosorbent assay nationallicence GT : Green tea nationallicence IL-1 : Interleukin-1 nationallicence IL-8 : Interleukin-8 nationallicence IAEC : Institutional Animal Ethics Committee nationallicence IBD : Inflammatory bowel disease nationallicence MDA : Malondialdehyde nationallicence MPO : Myeloperoxidase nationallicence NF-κB : Nuclear factor kappa-light-chain-enhancer of activated B cells nationallicence PPAR γ : Peroxisome proliferator activated receptor γ nationallicence RXR : Retinoid X receptor nationallicence SD : Standard deviation nationallicence SZ : Sulfasalazine nationallicence Sp1 : Specificity protein nationallicence TNF-α : Tumor necrosis factor-α nationallicence TNBS : Tri nitro benzene sulfonic acid nationallicence TZDs : Thiazolidinediones nationallicence UC : Ulcerative colitis nationallicence Byrav D. Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India aut Medhi B. Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India aut Vaiphei K. Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India aut Chakrabarti A. Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India aut Khanduja K. Department of Biophysics, Postgraduate Institute of Medical Education and Research, Chandigarh, India aut Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/5(2011-05-01), 1369-1378 0163-2116 56:5<1369 2011 56 10620 https://doi.org/10.1007/s10620-010-1446-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10620-010-1446-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Byrav D. Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India aut NATIONALLICENCE 700 1- Medhi B. Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India aut NATIONALLICENCE 700 1- Vaiphei K. Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India aut NATIONALLICENCE 700 1- Chakrabarti A. Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India aut NATIONALLICENCE 700 1- Khanduja K. Department of Biophysics, Postgraduate Institute of Medical Education and Research, Chandigarh, India aut NATIONALLICENCE 773 0- Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/5(2011-05-01), 1369-1378 0163-2116 56:5<1369 2011 56 10620 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer